NYSE: BSX · Medical Devices
Boston Scientific (BSX) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Boston Scientific (BSX) at $52.05 a share. The stock last closed at $43.64, which puts the model's fair value 19.3% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 18 Nov 2026. Boston Scientific Corporation.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 held the fair value at $52.05, within 1% of the run of 7 Nov 2026.
What the model makes of itThe price of $43.64 is 19.3% below it: Undervalued, on a medium evidence grade.
What's nextNext report on 3 Feb 2027. Options prices imply a move of about 11% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give BSX?
The calibrated range for BSX over 63 trading days is $38.27 to $50.10. It sits around the last close, and its width comes from the volatility that BSX's own options imply (40% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $39.50 to $67.38. In 68% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Boston Scientific Corporation (BSX) operates as a global leader in medical technology. It designs, manufactures and commercialises innovative medical devices for interventional medical specialties.
Faircurve's model put the fair value at $52.05 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $51.71, so the fair value moved +0.7%. The sheet gives no reason for the move. The calibrated range over 63 trading days is $37.95 to $49.10. Ranges built this way held the price 60% of the time at this horizon, based on 8,038 past valuations. The model grades the evidence Medium. The grade looks at input completeness, the number and agreement of comparable companies, and the width of outcomes. It does not say whether the fair value is right.
Boston Scientific has an overall quality score of 58 out of 100 against comparable companies. Capital discipline is its strongest factor, at 75, with net buybacks of 3.1% of market value against a peer median of 0.6%. Profitability scores 88, with ROIC of 11.4% against a peer median of 10.3%. Earnings quality scores 17, with FCF to net income of 0.95x against a peer median of 1.13x. The model compares it with Edwards Lifesciences, GE HealthCare, Stryker, Medtronic, DexCom, Abbott and Zimmer Biomet.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does BSX report earnings, and how has the stock reacted?
Boston Scientific's next earnings report is scheduled for 3 Feb 2027. Companies can move their dates.
Options prices on 18 Nov 2026 imply a move of about 5.0% in either direction through the nearest expiry, about 8 days out. That is the size the market is pricing, not a direction. BSX's 30 day implied volatility works out to about 11.5% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across BSX's last 8 reports, ignoring direction, was 4.1%.
What the options market has priced for a month's move in BSX
How does BSX score on business quality?
Boston Scientific's overall quality score is 58 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 88 | 11.4%ROIC | 10.3% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 17 | 0.95xFCF / net income | 1.13x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 56 | 19.9%Revenue growth, trailing | 9.8% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 75 | 3.1%Net buybacks / market value | 0.6% |
| Balance sheetNet debt to EBITDA and interest coverage. | 45 | 2.10xNet debt / EBITDA | 1.25x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 50 | 1.2 ptsEBITDA margin downside volatility, 5y | 1.2 pts |
How does BSX compare with similar companies?
The companies in medical devices closest to Boston Scientific in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| EW Edwards Lifesciences Corporation | $105.23 | $88.12 | -16.3% | Overvalued |
| GEHC GE HealthCare Technologies Inc. | $83.66 | $90.03 | +7.6% | Fairly valued |
| SYK Stryker Corporation | $318.15 | $277.20 | -12.9% | Fairly valued |
| MDT Medtronic Plc | $100.72 | $100.47 | -0.2% | Fairly valued |
| DXCM DexCom, Inc. | $82.52 | $73.84 | -10.5% | Fairly valued |
| ABT Abbott Laboratories | $104.48 | $106.73 | +2.2% | Fairly valued |
| ZBH Zimmer Biomet Holdings, Inc. | $103.32 | $120.99 | +17.1% | Undervalued |
| GKOS Glaukos Corporation | $233.08 | $228.07 | -2.1% | Data under review |
What the comparable companies' multiples alone would give for BSX, the peer-implied price, is $67.21 a share on this run. The fair value weighs that against the company's own multiple.
Boston Scientific at a glance
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the.
- Market value
- $64.3B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $20.8B
- Consensus revenue growth, next fiscal year
- +4.5%
- Analysts with estimates
- 16
- Beta to the US market
- 0.17
- First valued by Faircurve
- 1 May 2026
At the close of 18 Nov 2026, 60.4% of the 1,083 graded US stocks the model covers traded below the model's fair value. BSX was among them.
How the fair value is worked out: the model prices Boston Scientific on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for BSX was $51.71. As of 14 Nov 2026 it is $52.05, a change of +0.7%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Boston Scientific's valuation
Is Boston Scientific stock undervalued or overvalued?
On Faircurve's model, BSX reads as Undervalued as of 14 Nov 2026. The model's fair value is $52.05 a share against a last close of $43.64, a gap of +19.3%.
What is BSX's fair value?
$52.05 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $39.50 to $67.38.
What price range does the model give BSX?
$38.27 to $50.10 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Boston Scientific report earnings next?
The next report is scheduled for 3 Feb 2027. Companies can move their dates.
How much has BSX moved on past earnings reports?
Across its last 8 reports the median two session move was 4.1%, ignoring direction. The largest was -15.3% around the report of 4 Feb 2026.
How confident is the model in this valuation?
The model's evidence grade for BSX is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on BSX
The model holds no idea open on BSX today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on BSX with their outcomes. A free account is enough.